Here's why the BARD1 (ASX:BD1) share price is falling 7% today

The market is responding poorly to BARD1's fourth-quarter activities

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The BARD1 Life Sciences Ltd (ASX: BD1) share price is slipping after the company released its latest quarterly report.

BARD1's quarterly activities report for the 3 months ended 30 June details a seemingly good period for the company.

However, the market isn't responding positively to BARD1's news. Right now, the BARD1 share price is $1.35 – 7.51% lower than its previous closing price.

Let's take a closer look at today's news from BARD1.

The news driving the BARD1 share price today

Financials

The BARD1 share price is slipping on the back of its quarterly performance.

Over the quarter ended 30 June, BARD1 used $964,000 in its operating activities. The company spent $63,000 on patent fees, $288,000 on staffing, and $587,000 on admin and corporate costs.

It also spent $867,000 on research and development. However, BARD1 claims it received a $644,000 research and development tax incentive refund.

It also received $184,000 from sales of its hTERT product.

BARD1 ended the financial year with around $4.99 million in the bank. That's enough to fund its operations for another 5 quarters.

Activities

Over the quarter, BARD1 advanced its sales and commercial activities for its 3 major products. Unfortunately, the productive quarter isn't reflected in the BARD1 share price movements today.

BARD1's product hTERT performed well over the period, with sales increasing by 30% over the 2021 financial year. An Australian patent was granted for hTERT in March.

The company launched its EXO-NET product in May. BARD1 plans to embed the EXO-NET's technology into the discovery, research and development phases for multiple diagnostic and therapeutic applications.

BARD1 is also working on its SubBSM product, with a manuscript having been submitted to a peer reviewed journal in June.  

Additionally, positive results from a study using BARD1's autoantibody test to detect early ovarian cancer were published by a peer reviewed journal in late June.

Finally, in April BARD1 announced an options agreement with the University of Liverpool to licence 2 novel protein markers for development and commercialisation of the novel type 3c diabetes (T3cDM) blood test.

BARD1 share price snapshot

Despite today's dip, the BARD1 share price has been performing well lately. It has gained 108% since the start of 2021. It is also 48% higher than it was this time last year.

The company has a market capitalisation of around $131 million, with approximately 80 million shares outstanding.  

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. 

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »

Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23
Healthcare Shares

Pro Medicus shares climb 33% in less than a month, have I missed the dip?

Pro Medicus shares have soared. Is it the right time to invest?

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords share just rocketed 19% on BIG news

Investors are sending this ASX All Ords share flying on Monday. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Healthcare Shares

Why is this ASX All Ords stock surging 14% today?

This stock is starting the week strongly. But why? Let's find out.

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »